The Claim
Once-weekly subcutaneous retatrutide is associated with increased rates of nausea, vomiting, constipation, and hypersensitivity reactions compared to placebo in adults with overweight, obesity, and/or type 2 diabetes, suggesting a predictable but non-severe safety profile.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
Taking a weekly shot of retatrutide might make you feel more nauseous, throw up, get constipated, or have allergic reactions than if you took a fake shot — but these side effects aren’t life-threatening and are kind of expected.
See the scientific wording
Once-weekly subcutaneous retatrutide is associated with increased rates of nausea, vomiting, constipation, and hypersensitivity reactions compared to placebo in adults with overweight, obesity, and/or type 2 diabetes, suggesting a predictable but non-severe safety profile.
What the research says
1 studyThe study found that people taking this weekly shot for weight loss had more stomach issues like nausea and constipation, and some allergic reactions, but nothing too serious — just like the claim says.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.